

IL13

Research Grade Cendakimab

Catalog No.	DHE07701A	Quantity:	100 µg
	DHE07701B		1.0 mg

Alternate Names: Interleukin-13, IL-13, ABT-308, 13C5.5, RPC-4046

Description: Cendakimab (RPC-4046) is a humanized monoclonal antibody that targets IL-13 originally made by Celgene, acquired by Bristol-Myers Squibb that is being developed for the treatment of eosinophilic gastrointestinal disorders.

Concentration: 1.0 mg/ml, lot specific

UniProt ID (target): P35225

Source: XtenCHO cell line

Isotype: Human IgG1 kappa

INN: Cendakimab

Specificity: Human IL-13

Endotoxin: ≤ 0.01 EU/µg by LAL analysis

Formulation: 0.01M PBS, pH 7.4

Purification: Protein A/G affinity chromatography

Purity: > 95% as determined by SDS-PAGE

Storage & Stability: Recommended storage, undiluted at 2-8°C for up to 1 week, or in working aliquots at -20°C to -80°C for up to 1 year. **Avoid freeze/thaw cycles.**

NOT FOR HUMAN USE. FOR RESEARCH ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.



Cell Sciences®
65 Parker Street
Unit 11
Newburyport, MA 01950

Toll Free: 888-769-1246
Phone: 978-572-1070
Fax: 978-992-0298

E-mail: info@cellsciences.com
Website: www.cellsciences.com